Dr Ashutosh Wechalekar

Photo

Personal Profile

Name: Ashutosh Wechalekar Email: a.wechalekar@ucl.ac.uk
Title: Dr Tel:
Department: Inflammation Fax:
Position: Senior Clinical Lecturer Address: , , ,
Research Domain: Cancer Web Page:  

Profile

Research Description


Research Activities

AL amyloidosis

Amyloidosis and treatment of amyloidosis

Education Description

UCL Collaborators

Dr Alun Coker

External Collaborators

Publications

    2013

    • Merlini G, Wechalekar AD, Palladini G (2013). Systemic light chain amyloidosis: an update for treating physicians.. Blood, , - . doi:10.1182/blood-2013-01-453001
    • Lane T, Loeffler JM, Rowczenio DM, Gilbertson JA, Bybee A, Russell TL, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ (2013). Brief Report: AA Amyloidosis Complicating the Hereditary Periodic Fever Syndromes. ARTHRITIS AND RHEUMATISM, 65(4), 1116 - 1121. doi:10.1002/art.37827
    • Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ (2013). Senile systemic amyloidosis: clinical features at presentation and outcome.. J Am Heart Assoc, 2(2), e000098 - . doi:10.1161/JAHA.113.000098
    • Sattianayagam PT, Lane T, Fox Z, Petrie A, Gibbs SD, Pinney JH, Risom SS, Rowczenio DM, Wechalekar AD, Lachmann HJ, Gilbertson JA, Hawkins PN, Gillmore JD (2013). A prospective study of nutritional status in immunoglobulin light chain amyloidosis.. Haematologica, 98(1), 136 - 140. doi:10.3324/haematol.2012.070359
    • Sattianayagam PT, Gillmore JD, Pinney JH, Gibbs SD, Wechalekar AD, Gilbertson JA, Rowczenio D, Hawkins PN, Lachmann HJ (2013). Inflammatory Bowel Disease and Systemic AA Amyloidosis.. Dig Dis Sci, , - . doi:10.1007/s10620-012-2549-x
    • Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, Cox AT, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Moon JC (2013). Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study.. Circ Cardiovasc Imaging, 6(1), 34 - 39. doi:10.1161/CIRCIMAGING.112.978627
    • Pinney JH, Lachmann HJ, Sattianayagam PT, Gibbs SD, Wechalekar AD, Venner CP, Whelan CJ, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD (2013). Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance.. Am J Transplant, 13(2), 433 - 441. doi:10.1111/j.1600-6143.2012.04326.x
    • Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, Dungu J, Banyperasad SM, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD (2013). Systemic Amyloidosis in England: an epidemiological study.. Br J Haematol, 161(4), 525 - 532. doi:10.1111/bjh.12286

    2012

    • Roussel M, Palladini G, Gibbs SDJ, Venner CP, Fermand J-P, Lachmann HJ, Gillmore JD, Hawkins PN, Merlini G, Jaccard A, Wechalekar A (2012). Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis.
    • Roussel M, Palladini G, Gibbs SDJ, Venner CP, Fermand J-P, Lachmann HJ, Gillmore JD, Hawkins PN, Merlini G, Jaccard A, Wechalekar A (2012). Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis.
    • Mahmood S, Venner CP, Lane T, Rannigan L, Foard D, Pinney J, Banypersad S, Dungu J, Whelan C, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar A (2012). Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.
    • Venner CP, Lane T, Foard D, Rannigan L, Mahmood S, Gibbs SDJ, Pinney J, Banypersad S, Dungu J, Whelan C, Lachmann H, Gillmore JD, Hawkins PN, Wechalekar A (2012). A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.
    • Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD (2012). Updates in cardiac amyloidosis: a review.. J Am Heart Assoc, 1(2), e000364 - . doi:10.1161/JAHA.111.000364
    • Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G (2012). New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.. J Clin Oncol, 30(36), 4541 - 4549. doi:10.1200/JCO.2011.37.7614
    • Sattianayagam PT, Gibbs SD, Rowczenio D, Pinney JH, Wechalekar AD, Gilbertson JA, Hawkins PN, Lachmann HJ, Gillmore JD (2012). Hereditary lysozyme amyloidosis -- phenotypic heterogeneity and the role of solid organ transplantation.. J Intern Med, 272(1), 36 - 44. doi:10.1111/j.1365-2796.2011.02470.x
    • Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G (2012). Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.. Leukemia, 26(11), 2317 - 2325. doi:10.1038/leu.2012.100
    • Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2012). Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.. Blood, 119(19), 4387 - 4390. doi:10.1182/blood-2011-10-388462
    • Wechalekar AD, Hawkins PN (2012). AL amyloidosis: new drugs and tests, but old challenges.. Oncology (Williston Park), 26(2), 161 - 164.
    • Dungu J, Whelan CJ, Gibbs SD, Pinney JH, Banypersad SM, Venner CP, Lachmann HJ, Wechalekar A, Gillmore JD, Hawkins PN, Anderson L (2012). Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis.. J Cardiovasc Magn Reson, 14 Suppl 1, O87 - . doi:10.1186/1532-429X-14-S1-O87
    • Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, Rowczenio D, Pflugfelder PW, Fox Z, Lachmann HJ, Wechalekar AD, Hawkins PN, Gillmore JD (2012). Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.. Eur Heart J, 33(9), 1120 - 1127. doi:10.1093/eurheartj/ehr383
    • Dungu J, Sattianayagam PT, Whelan CJ, Gibbs SD, Pinney JH, Banypersad SM, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Hawkins PN, Anderson LJ (2012). The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients.. Am Heart J, 164(1), 72 - 79. doi:10.1016/j.ahj.2012.04.013

    2011

    • Page J, Wickham F, Burniston M, Quigley A, McCool D, Hawkins P, Wechalekar A (2011). SPECT-CT based quantitation for cardiac amyloidosis using DPD scintigraphy - a clinically useful method for differentiating transthyretin from AL amyloidosis. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 38, S210 - S210.
    • Hutt DF, Quigley AM, Hall ML, Reynolds S, Hawkins PN, Wechalekar AD (2011). Tc-99m-3,3-Diphosphono-1,2-Propanodicarboxylic Acid (Tc-99m DPD) scintigraphy - a novel imaging modality for systemic amyloidosis. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 38, S210 - S210.
    • Lane T, Rannigan L, Foard D, Wechalekar A, Gibbs S, Pinney J, Venner CP, Banypersad S, Lachmann H, Hawkins PN, Gillmore JD (2011). ALchemy - A Large Prospective 'Real World' Study of Chemotherapy in AL Amyloidosis.
    • Venner CP, Gillmore JD, Lane T, Foard D, Rannigan L, Gibbs SDJ, Pinney J, Whelan C, Lachmann H, Hawkins PN, Wechalekar A (2011). Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (> 75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival.
    • Venner CP, Gillmore JD, Lane T, Foard D, Rannigan L, Gibbs SDJ, Pinney J, Whelan C, Lachmann H, Hawkins PN, Wechalekar A (2011). Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival.
    • Wechalekar A, Schonland SO, Kastritis E, Hawkins PN, Dimopoulos MA, Russo P, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Gillmore JD, Merlini G, Palladini G (2011). European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease.
    • Sattianayagam P, Lane T, Risom S, Gibbs SD, Pinney JH, Wechalekar AD, Iachmann HJ, Philip HN, Gilmore JD (2011). A Prospective Study Assessing Nutritional Status in Treatment-NaiVE AL Amyloidosis Patients and the Effects of Malnutrition on Quality of Life and Survival.
    • Wechalekar AD (2011). ASCT for AL: all's well that ends well.. Blood, 118(16), 4298 - 4299. doi:10.1182/blood-2011-08-375105
    • Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, Wechalekar AD, Gilbertson JA, Hunt T, Gibbs SD, Sattianayagam PT, Pinney JH, Hawkins PN, Gillmore JD (2011). Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.. Am J Pathol, 179(4), 1978 - 1987. doi:10.1016/j.ajpath.2011.06.024
    • Pinney JH, Lachmann HJ, Gillmore JD, Wechalekar A, Gibbs SDJ, Sattianayagam P, Banypersad SM, Dungu J, Wassef N, McCarthy CA, Hawkins PN, Whelan CJ (2011). SENILE SYSTEMIC AMYLOIDOSIS: A COMMON CAUSE OF HEART FAILURE IN THE ELDERLY?. doi:10.1136/heartjnl-2011-300198.103
    • Wechalekar AD, Gillmore JD, Wassef N, Lachmann HJ, Whelan C, Hawkins PN (2011). Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis.. Haematologica, 96(7), 1079 - 1080. doi:10.3324/haematol.2011.040493
    • Sattianayagam P, Gibbs SD, Pinney JH, Wechalekar AD, Lachmann HJ, Philip HN, Rowczenio DM, Gilbertson JA, Gillmore JD (2011). The Role of Liver Transplantation in Hereditary Non-Neuropathic Systemic Amyloidosis.
    • Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, Sattianayagam PT, Gibbs SD, Orlandi E, Wassef NL, Bradwell AR, Hawkins PN, Gillmore JD (2011). Outcome in renal Al amyloidosis after chemotherapy.. J Clin Oncol, 29(6), 674 - 681. doi:10.1200/JCO.2010.30.5235
    • Lee L, Aziz M, Wechalekar A, Rabin N (2011). Coexistent asymptomatic myeloma and hereditary cardiac amyloidosis: an unusual case of heart failure.. Br J Hosp Med (Lond), 72(11), 650 - 651.

    2010

    • Dogan A, Theis JD, Vrana JA, Jimenez-Zepeda VH, Lacy MQ, Leung N, Dispenzieri A, Zeldenrust SR, Fonseca R, Gilbertson JA, Hunt T, Wechalekar AD, Lachmann HJ, Rowczenio D, Hawkins PN, Gillmore JD (2010). Clinical and pathological phenotype of leukocyte cell-derived chemotaxin-2 (LECT2) amyloidosis (ALECT2).
    • Whelan CJ, Pawarova B, De Cruz M, Lachmann HJ, Sattianayagam PT, Gibbs SDJ, Pinney JH, Gillmore JD, Hawkins PN, Wechalekar AD (2010). Assessment of left ventricular wall thickness in cardiac amyloidosis by different imaging modalities.
    • Gibbs SDJ, Gillmore JD, Sattianayagam PT, Lachmann HJ, Lane T, Goodman HJB, Offer M, Whelan CJ, Rowczenio DM, Hutt DF, Gilbertson JA, Hawkins PN, Wechalekar AD (2010). CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched case-control study.
    • Rowczenio DM, Lachmann HJ, Gibbs SDJ, Gilbertson JA, Hunt T, Russell TL, Sattianayagam PT, Trojer H, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD (2010). Experience of ATTR in a single centre: findings among 220 patients.
    • Rowczenio DM, Lachmann HJ, Gibbs SDJ, Gilbertson JA, Hunt T, Russell TL, Sattianayagam PT, Trojer H, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD (2010). Hereditary systemic amyloidosis associated with three novel apolipoprotein AI variants.
    • Gibbs SDJ, Pinney JH, Sattianayagam PT, Wechalekar AD, Lane T, Rowczenio DM, Offer M, Gilbertson JA, Hunt T, Hawkins PN, Gillmore JD, Lachmann HJ (2010). Light chain deposition disease (LCDD): a case series of 24 patients.
    • Gilbertson JA, Hunt T, Wechalekar AD, Lachmann HJ, Hawkins PN, Gillmore JD (2010). Localised amyloid at injection sites derived from porcine and human insulin.
    • Sattianayagam PT, Rowczenio DM, Gibbs SDJ, Trojer H, Russell TL, Pinney JH, Lachmann HJ, Wechalekar AD, Hawkins PN, Pepys MB, Gilbertson JA, Hunt T, Gillmore JD (2010). Natural history of hereditary lysozyme amyloidosis.
    • Wechalekar AD, Merlini G, Gillmore JD, Russo P, Lachmann HJ, Perlini S, Whelan CJ, Hawkins PN, Palladini G (2010). N-terminal fragment of brain natriuretic peptide (NT-ProBNP) - a new response criterion in AL amyloidosis.
    • Palladini G, Hawkins PN, Foli A, Lachmann HJ, Perlini S, Gillmore J, Merlini G, Wechalekar AD (2010). N-terminal pro natriuretic peptide type B ( NT-proBNP) is a reliable marker of cardiac response in patients with AL amyloidosis and renal failure.
    • Sattianayagam PT, Hahn A, Gibbs SDJ, Whelan CJ, Rowczenio DM, Trojer H, Russell TL, Pinney JH, Lachmann HJ, Wechalekar AD, Hawkins PN, Gilbertson JA, Hunt T, Gillmore JD (2010). Phenotype and natural history of transthyretin alanine 60 ( T60A) amyloidosis.
    • Gibbs SDJ, Sattianayagam PT, Whelan CJ, De Cruz M, Abreu JM, Pinney JH, Pawarova B, Wassef NL, Lane T, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2010). Rise in serum NT pro-BNP associated with chemotherapy in patients with AL amyloidosis: implications for organ response assessment.
    • Hutt DF, Lane T, Gillmore JD, Lachmann HJ, Gibbs SDJ, Sattianayagam PT, Gopaul D, Quigley AM, Hawkins PN, Wechalekar AD (2010). Role of dual modality I123 serum amyloid P component SPECT-CT imaging in amyloidosis.
    • Wechalekar AD, Harding S, Lachmann HJ, Gillmore JD, Wassef NL, Thomas M, Gibbs SDJ, Sattianayagam P, Whelan CJ, Bradwell AR, Hawkins PN (2010). Serum immunoglobulin heavy/light chain ratios (HevyLite) in patients with systemic AL amyloidosis.
    • Sattianayagam PT, Gibbs SDJ, Wechalekar AD, Lachmann HJ, Whelan CJ, Pinney JH, Hawkins PN, Gillmore JD (2010). Solid organ transplantation in AL amyloidosis.
    • Lachmann HJ, Gillmore JD, Wechalekar AD, Sattianayagam PT, Gibbs SDJ, Pinney JH, Goodman HJB, Offer M, Gallimore JR, Gilbertson JA, Hunt T, Gopaul D, Hutt DF, Hawkins PN (2010). Survival on dialysis and outcome after renal transplantation in AA amyloidosis.
    • Gillmore JD, Cocks K, Gibbs SDJ, Sattianayagam P, Lane T, Lachmann HJ, Schey S, Cavenagh J, Oakervee H, Morgan G, Bourne S, Skinner E, Bell S, Booth G, Foard DM, Mehta A, Hawkins PN, Wechalekar AD (2010). UK AL Amyloidosis Treatment Trial (UKATT) - a randomised study: lessons for future trial design.
    • Hunt T, Gilbertson JA, Lachmann HJ, Gillmore JD, Gibbs SDJ, Sattianayagam PT, Whelan CJ, Hawkins PN, Wechalekar AD (2010). Unraveling the clonal B cell disease underlying localised AL amyloidosis.
    • Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G (2010). Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.. J Clin Oncol, 28(6), 1031 - 1037. doi:10.1200/JCO.2009.23.8220
    • Gibbs SDJ, Sattianayagam PT, Pinney JH, Gilbertson JA, Lachmann HJ, Wechalekar AD, Hawkins PN, Gillmore JD (2010). Renal biopsy is a relatively safe procedure in cases of suspected amyloidosis and a valuable tool in excluding non-AL forms of the disease. INTERN MED J, 40(2), 167 - 168. doi:10.1111/j.1445-5994.2009.02127.x
    • Shah AD, Watts AJ, Mehta AB, Wechalekar AD (2010). An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis.. Int J Hematol, 91(1), 121 - 123. doi:10.1007/s12185-009-0460-9
    • Sattianayagam PT, Gibbs SDJ, Wechalekar AD, Lachmann HJ, Hawkins PN, Gillmore JD (2010). Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. American Journal of Transplantation, 9(10), 2443 - 2443. doi:10.1111/j.1600-6143.2009.02790.x
    • Whelan CJ, Pawarova B, De Cruz M, Lachmann HJ, Sattianayagam PT, Gibbs SDJ, Pinney JH, Gillmore JD, Wassef N, Hawkins PN, Wechalekar AD (2010). Changes in serum NT-proBNP correlate with changes in both systolic and diastolic function in AL amyloidosis.
    • Wechalekar AD, Kastritis E, Merlini G, Hawkins PN, Dimopoulos MA, Gillmore JD, Gibbs SDJ, Palladini G (2010). A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis.
    • Wechalekar AD, Kastritis E, Merlini G, Hawkins PN, Dimopoulos MA, Gillmore JD, Gibbs SDJ, Palladini G (2010). A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis.
    • Lachmann HJ, Harding S, Wechalekar A, Gillmore JD, Amft EN, Hawkins PN (2010). Remarkable Efficacy of IL 1 Receptor Antagonist In Schnitzler's Syndrome a Series of 6 Cases.
    • Lachmann HJ, Harding S, Wechalekar A, Gillmore JD, Amft EN, Hawkins PN (2010). Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases.
    • Palladini G, Dispenzien A, Gertz MAA, Wechalekar A, Hawkins PN, Schonland SO, Hegenbart U, Comenzo RL, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G (2010). Validation of the Criteria of Response to Treatment In AL Amyloidosis.
    • Palladini G, Dispenzieri A, Gertz MAA, Wechalekar A, Hawkins PN, Schonland SO, Hegenbart U, Comenzo RL, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G (2010). Validation of the Criteria of Response to Treatment In AL Amyloidosis.
    • Grünfeld JP (2010). Systemic diseases: from amyloidosis to cryoglobulinemia.. Clin J Am Soc Nephrol, 5(11), 1912 - 1915. doi:10.2215/CJN.08130910
    • Sattianayagam PT, Gibbs SDJ, Pinney JH, Wechalekar AD, Lachmann HJ, Whelan CJ, Gilbertson JA, Hawkins PN, Gillmore JD (2010). Solid Organ Transplantation in AL Amyloidosis. AM J TRANSPLANT, 10(9), 2124 - 2131. doi:10.1111/j.1600-6143.2010.03227.x
    • Gibbs S, Vanderpump M, Hutt D, Sattianayagam P, Pinney J, Wassef N, Gillmore J, Lachmann H, Hawkins P, Wechalekar A (2010). AN ANALYSIS OF THE ENDOCRINE DISEASE ASSOCIATED WITH SYSTEMIC AL AMYLOIDOSIS.
    • Ahmed O, Lentaigne C, Wright F, McAleese D, Dangwa F, Wechalekar A, Hughes D, Mehta A, McNamara C (2010). CD56 EXPRESSION AND TREATMENT OUTCOME WITH BORTEZOMIB THERAPY IN PATIENTS WITH RELAPSED PLASMA CELL MYELOMA.
    • Gibbs S, Pinney J, Sattianayagam P, Lane T, Rowczenio D, Wechalekar A, Hunt T, Gilbertson J, Hawkins P, Gillmore J, Lachmann H (2010). LIGHT CHAIN DEPOSITION DISEASE (LCDD) VERSUS AL AMYLOIDOSIS: DIFFERENCES IN NATURAL HISTORY AND TREATMENT?.
    • Gillmore JD, Lachmann HJ, Wechalekar A, Hawkins PN (2010). Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation.. Blood, 115(21), 4313 - . doi:10.1182/blood-2010-01-261750
    • Lane T, Foard DM, Wechalekar AD, Gibbs SDJ, Lachmann HJ, Sattianayagam PT, Pinney JH, Rannigan LG, Gillmore JD, Hawkins PN (2010). ALchemy - a nationwide study of chemotherapy for systemic AL amyloidosis in the UK.
    • Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, Sattianayagam PT, Gibbs SDJ, Orlandi E, Wassef NL, Bradwell AR, Hawkins PN, Gillmore JD (2010). Clinical outcome of systemic AL amyloidosis affecting the kidneys.

    2009

    • Wechalekar AD, Wassef NL, Gibbs SDJ, Gillmore J, Dike F, Lachmann H, Sattianayagam P, Bradwell A, Hawkins PN (2009). A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP..
    • Gillmore J, Cocks K, Gibbs SDJ, Sattianayagam PT, Lane T, Lachmann H, Schey S, Cavenagh JD, Oakervee H, Morgan GJ, Mehta AB, Bourne S, Skinner E, Booth G, Hawkins PN, Wechalekar AD (2009). Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis - Results From the UK Amyloidosis Treatment Trial.
    • de Cruz M, Pawarova B, Lachmann H, Gillmore J, Gibbs S, Sattianayagam P, Hawkins P, Wechalekar AD (2009). Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.
    • Gibbs SDJ, Gillmore JD, Sattianayagam PT, Offer M, Lachmann HJ, Hawkins PN, Wechalekar AD (2009). In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.
    • Gibbs SDJ, Sattianayagam PT, Gillmore JD, Offer M, Lachmann HJ, Hawkins PN, Wechalekar AD (2009). Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.
    • Gibbs SDJ, De Cruz M, Sattianayagam PT, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2009). Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment..
    • Wechalekar AD, Wassef N, Lachmann H, Sattianayagam P, Gibbs SDJ, Gillmore J, Hawkins PN (2009). HIGH EARLY MORTALITY AND POOR OUTCOMES FOR PATIENTS WITH AL AMYLOIDOSIS PRESENTING WITH HIGH SERUM FREE LIGHT CHAINS - A NEW RISK STRATIFICATION MODEL.
    • Sattianayagam P, Gibbs SD, Wechalekar A, Gilbertson JA, Lachmann HJ, Philip HN, Gillmore JD (2009). Systemic AA Amyloidosis in Crohn's Disease (CD): A Serum Amyloid P Component (SAP) Scintigraphy Study.
    • Wechalekar A, Merlini G, Gillmore JD, Russo P, Lachmann HJ, Obici L, Hawkins PN, Palladini G (2009). A New Method of Response Assessment in AL Amyloidosis Using NT-ProBNP with Hematologic Response. CLIN LYMPHOMA MYELOM, 9, S51 - S51.
    • Wechalekar A, Hawkins PN, Wassef NJ, Gillmore ND, Lachmann HJ, Morris J, Thomas M, Bradwell AR, Mead G (2009). Monoclonal Protein Detection in AL Amyloidosis Revisited: Analysis of 642 Patients. CLIN LYMPHOMA MYELOM, 9, S49 - S49.
    • Gibbs SD, Sattianayagam PT, Wechalekar AD, Lachmann HJ, Hawkins PN, Gillmore JD (2009). Solid Organ Transplantation in AL Amyloidosis: Lessons Learned and Its Current Role. CLIN LYMPHOMA MYELOM, 9, S71 - S71.
    • Lyengar S, Ayto R, Wechalekar A, Dwanga F, Mehta AB, Hughes DA (2009). A clinical audit of venous thromboprophylaxis in multiple myeloma.
    • Wechalekar AD, Offer M, Gillmore JD, Hawkins PN, Lachmann HJ (2009). Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation.. Nature Clinical Practice Cardiovascular Medicine, 6(2), 128 - 133.
    • Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS, Wechalekar A, Hawkins PN (2009). Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis.. Journal of the American Society of Nephrology, 20(2), 444 - 451.
    • Sattianayagam PT, Gibbs SD, Wechalekar AD, Lachmann HJ, Hawkins PN, Gillmore JD (2009). Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. American Journal of Transplantation, 10, 2443 - .

    2008

    • Wechalekar AD, Lachmann HJ, Goodman HJ, Bradwell A, Hawkins PN, Gillmore JD (2008). AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood, 112(10), 4009 - 4016.
    • Lachmann HJ, Wechalekar AD, Gillmore JD (2008). High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.. N Engl J Med, 358(1), 91 - 92.
    • Wechalekar AD, Hawkins PN, Gillmore JD (2008). Perspective in treatment of amyloidosis. British Journal of Haematology, 140(4), 365 - 377.
    • Wechalekar A, Lachmann H, Gillmore J, Offer M, Joshi J, Hawkins P (2008). NT-ProBNP in AL amyloidosis: association with survival and changes after chemotherapy.
    • Lachmann HJ, Goodman HJB, Gillmore JD, Wechalekar A, Rowczenio DM, Bybee A, Hawkins PN (2008). Comparison of cardiac amyloidosis associated with wild type transthyretin and the isoleucine 122 variant.
    • Offer M, Wechalekar AD, Lachmann HJ, Gillmore JD, Hawkins PN (2008). AL amyloidosis in the elderly: A review of 330 patients.
    • Wechalekar AD, Lachmann HL, Offer M, Hawkins PN, Gillmoe JD (2008). Efficacy of bortezomib in systemic AL amyloidosis with relapse/refractory clonal disease.. Haematologica, 93(2), 295 - 298.
    • Gibbs SDJ, Sattianayagam PT, Lachmann HJ, Offer M, Gillmore JD, Hawkins PN, Wechalekar A (2008). Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.
    • Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G (2008). Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis.
    • Wechalekar A, Merlini G, Gillmore JD, Russo P, Lachmann HJ, Obici L, Hawkins PN, Palladini G (2008). Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.

    2007

    • Wechalekar AD, Gillmore JD, Lachmann HJ, Offer M, Hawkins PN (2007). Clinical profile and treatment outcome in 103 patients with al amyloidosis associated with IGM paraproteinaemia.
    • Wechalekar AD, Parande CM (2007). Haematological malignancies in developing countries: is CML the commonest childhood leukaemia?. Leukemia, 21(10), 2194 - . doi:10.1038/sj.leu.2404880
    • Wechalekar AD, Lachmann HJ, Gillmore JD, Hawkins PN (2007). Abnormal NT-ProBNP in AL amyloidosis patients without cardiac involvement at diagnosis - A predictor of subsequent cardiac involvement.
    • Wechalekar AD, Lachmann HJ, Gillmore JD, Hawkins PN (2007). A profile of 44 long term survivors (> 10yrs) with AL amyloidosis.
    • Wechalekar AD, Gillmore JD, Lachmann HJ, Offer M, Hawkins PN (2007). NT-ProBNP in AL amyloidosis: association with survival and changes after chemotherapy.
    • Offer M, Wechalekar AD, Gilmore JD, Lachmann HJ, Hawkins PN (2007). Natural history and outcome of amyloidosis in the elderly.
    • Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD (2007). Safety and efficacy of risk adapted cyclophosphamide,thalidomide and dexamethasone in systemic AL amyloidosis. Blood, 109(2), 457 - 464. doi:10.1182/blood-2006-07-035352

    2006

    • Rowczenio DM, Lachmann HJ, Gillmore JD, Wechalekar AD, Gilbertson JA, Goodman HJB, Hawkins PN, Bybee A (2006). Screening for patients with hereditary systemic amyloidosis.
    • Hawkins PN, Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Gillmore JD (2006). Safety and efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis.
    • Wechalekar AD, Lachmann HJ, Gillmore JD, Offer M, Joshi JJ, Hawkins PN (2006). NT-ProBNP in AL amyloidosis: changes after chemotherapy and association with survival.
    • Offer M, Wechalekar AD, Gillmore JD, Lachmann HJ, Hawkins PN (2006). Natural history and outcome of amyloidosis in the elderly.
    • Wechalekar A, Gillmore J, Lachmann H, Offer M, Hawkins P (2006). Efficacy and safety of bortezomib in systemic AL amyloidosis - A preliminary report..
    • Joshi J, Wechalekar AD, Bourdillon PJ, Joshi RP, Rahemtulla A, Hawkins PN (2006). Images in cardiovascular medicine. Intermittent loss of second heart sound.. Circulation, 114(22), e612 - e613. doi:10.1161/CIRCULATIONAHA.106.638510
    • Gillmore JD, Stangou AJ, Lachmann HJ, Goodman HJ, Wechalekar AD, Acheson J, Tennent GA, Bybee A, Gilbertson J, Rowczenio D, O'Grady J, Heaton ND, Pepys MB, Hawkins PN (2006). Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant, 6(10), 2342 - 2347. doi:10.1111/j.1600-6143.2006.01507.x
    • Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN (2006). Outcome of autologous transplantation for AL amyloidosis in the UK. British Journal of Haematology, 134(4), 417 - 425.
    • Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN (2006). Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 107(3), 1227 - 1229. doi:10.1182/blood-2005-08-3253
    • Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, Cabanas ED, Parker T, Nightingale M, Wechalekar A, Orchard KH, Harrison CJ, Cross NC, Morgan GJ, Ross FM (2006). Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma.. Leukemia, 20(9), 1610 - 1617. doi:10.1038/sj.leu.2404304

    2005

    • Gillmore JD, Wechalekar AD, Goodmarn HJB, Lachmann HJ, Offer M, Joshi J, Hawkins RN (2005). Cardiac followed by autologous stem cell transplantation for systemic AL amyloidosis..
    • Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Offer M, Bradwell AR, Hawkins PN (2005). Clinical profile and treatment outcome in 92 patients with AL amyloidosis associated with IgM paraproteinaemia..
    • Chiecchio L, Protheroe RKM, Parker T, Rudduck C, Cheung KL, Dagrada G, Wechalekar A, Nightingale M, Harrison CJ, Cross NCP, Ross FM (2005). Critical importance of conventional cytogenetics in detecting prognostically significant chromosome 13 deletions in myeloma..
    • Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Offer M, Bradwell AR, Hawkins PN (2005). Efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis..
    • Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D (2005). IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.. Ann Hematol, 84(2), 115 - 117. doi:10.1007/s00277-004-0944-x
    • Wechalekar AD, Lachmann HJ, Gillmore JD, Goodman HJB, Offer M, Hawkins PN (2005). The role of renal transplantation in systemic AL amyloidosis..
    • Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M (2005). Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation.. Clin Lab Haematol, 27(4), 247 - 249. doi:10.1111/j.1365-2257.2005.00699.x
    • Goodman HJ, Wechalekar AD, Hawkins PN (2005). Amyloidosis, not myeloma.. Br J Haematol, 129(1), 158 - 159. doi:10.1111/j.1365-2141.2005.05441.x
    • Offer M, Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Bradwell AR, Hawkins PN (2005). Standard oral melphalan chemotherapy for AL amyloidosis revisited using the serum free light chain assay..

    2004

    • Wechalekar A, Orchard K, Lachmann H, Ross F, Hawkins P, Harrison C (2004). Impact of chromosomal abnormalities revealed by interphase FISH on survival in primary light chain amyloidosis..
    • Mollee PN, Wechalekar AD, Pereira DL, Franke N, Reece D, Chen C, Stewart AK (2004). Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.. Bone Marrow Transplant, 33(3), 271 - 277. doi:10.1038/sj.bmt.1704344
    • Chang H, Wechalekar A, Li L, Reece D (2004). Molecular cytogenetic abnormalities in patients with concurrent chronic lymphocytic leukemia and multiple myeloma shown by interphase fluorescence in situ hybridization: evidence of distinct clonal origin.. Cancer Genet Cytogenet, 148(1), 44 - 48.

    2003

    • Wechalekar AD, Chen CI, Sutton D, Reece D, Voralia M, Stewart AK (2003). Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.. Leuk Lymphoma, 44(7), 1147 - 1149. doi:10.1080/1042819031000067918
    • Lachmann HJ, McDermott MF, Hawkins PN (2003). AA amyloidosis complicating the hereditary periodic fever syndromes..

    2002

    • Wechalekar AD, Reece D, Sutton D, Franke N, Chen C, Stewart AK (2002). A study of autologous stem cell transplantation in young patients with multiple myeloma..
    • Mollee PN, Wechalekar AD, Pereira DL, Franke N, Reece D, Chen C, Stewart AK (2002). Autologous stem cell transplantation (ASCT) in primary systemic amyloidosis (AL): The impact of selection criteria on outcome..
    • Wechalekar A, Chen C, Amato D, Sutton D, Stewart AK, Reece D (2002). IgD multiple myeloma - A clinical profile and a comparison of autologous stem cell transplantation with standard chemotherapy..

    2001

    • Wechalekar AD, Sutton D, Voralia M, Stewart AK, Chen CI (2001). Intermediate dose thalidomide (200mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.. BLOOD, 98(11), 162A - 162A.

    2000

    • Wechalekar A, Ganczakowski M, Cranfield TG, Sinclair D, Prentice HG, Goldman JM, Bell AJ (2000). Occurrence of autoantibodies in patients developing graft versus host disease after allogeneic bone marrow transplant.. BLOOD, 96(11), 198A - 198A.
    • Wechalekar A, Parapia L (2000). Hereditary haemorrhagic telangiectasia with protein S deficiency in a family: a case report.. Eur J Haematol, 64(1), 59 - 60.